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Sodium (E)-{N-[2-methyloxy-5-(2,4,6-trimethoxy-styryl 
sulfonyl)methylenephenyl]amino}acetate (ON 01910.Na, 
Onconova Therapeutics Inc., Fig. 1) is a novel anticancer agent 
currently in phase I clinical trials in patients. ON 01910 is a cell-
cycle inhibitor and selectively causes mitotic arrest by creating 
spindle abnormalities and abnormal centrosome localization and 
fragmentation leading to apoptosis in cancer cells. It has been 
shown to inhibit PLK1 pathway activity at a nanomolar range in 
a substrate-dependent and ATP-independent manner, although 
targeting other kinases has also been reported.
1
,
2
 This compound 
inhibits a broad spectrum of human tumour cells growth with 
GI50 values in the nanomolar range and is active in a number of 
human xenografts in mice
3,4
. Currently, the drug is in several 
phase I and II clinical trials in adult patients with a variety of 
solid tumours as well as hematological malignancies.
5-8
 Anti-
tumour activity was observed in all phase I trials. Recent phase I 
studies in human B-cell chronic lymphocytic leukaemia (CLL) 
demonstrated that ON 01910.Na selectively induced apoptosis in 
all CLL samples tested and reduced PLK1 activity in the 
leukeamic cells .
3
 ON 01910.Na is currently also being tested in 
phase I combination therapy in patients with solid tumors. 
Our efforts to develop small molecule cell-cycle inhibitors 
for cancer therapy has resulted in the development of several 
classes of CDK and Aurora kinase inhibitors.
9-13
 In the 
process of designing novel class PLK1 inhibitors we prepared 
and evaluated the biological activity of ON 01910 and several 
derivatives. The structure activity relationship established has 
provided guidance for us to rapidly progress our drug 
discovery programme. Here we report the synthesis and 
biological evaluation of analogue benzylstyrylsulfones, 
benzylstyrylsulfines and benzylsulfonyl-N-phenylacetamides 
(Type-I, -II and -III, Fig. 1). This study suggests that the 
benzylstyrylsulfinyl chemotype offers great potential for 
development of anti-cancer agents. 
 
 
 
Fig. 1 Structures of ON 01910.Na and the designated derivatives 
 
The synthetic chemistry employed to prepare type I-III 
compounds is outlined in Scheme 1. The synthesis started from 
2-(4-methoxy-3-nitrobenzylthio)acetic acid 1, which can be 
obtained by halogenation of 1-methoxy-4-methyl-2-nitrobenzene 
followed by treatment with 2-mercaptoacetic acid.
14,15
 2-(4-
Methoxy-3-nitrobenzylsulfonyl)acetic acid 2 or 2-(4-methoxy-3-
nitrobenzylsulfinyl)acetic acid 5 were obtained by 
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chemoselective oxidation of 1. Doebner modification of 
Knoevenagel condensation
16
 between 2 or 5 with substituted 
aromatic aldehyde in pyridine and catalytic amounts of piperidine 
yielded the corresponding (E)-1-methoxy-2-nitro-4-
(styrylsulfonylmethyl)benzene 3a, 3b, 3c and 3d (R’=NO2, 
Scheme 1 and Table 1) or (E)-1-methoxy-2-nitro-4-
(styrylsulfinylmethyl)benzene 6 (R=2,4,6-trimethoxyl). 
Reduction of 3a, 3b, 3c or 3d, as well as 6 resulted in their 
respective anilino derivatives 3e, 3f, 3g, 3h and 7. Acylation of 
3e (R’=NH2, R=2,4,6-(OMe)3) with acylchloride afforded 3i 
(R’=NHCOMe, R=2,4,6-(OMe)3, Table 1). Treatment of 3e with 
ethyl 2-bromoacetate in the presence of sodium acetate followed 
by hydrolysis in aqueous sodium carbonate yielded 3j 
(R’=NHCH2COOH, R=2,4,6-(OMe)3, e.g. ON 01910).  
To prepare chemotype-III sulfonyl-N-phenyl acetamides (Fig. 
1) 2-(4-methoxy-3-nitrobenzylsulfonyl)acetic acid 2 was 
converted to 2-(4-methoxy-3-nitrobenzylsulfonyl)acetyl chloride. 
The later, treated with various substituted anilines, resulted in 4a, 
4b, 4c, 4d and 4e. Reduction of 4a and 4b in the presence of tin 
chloride generated 4f and 4g respectively.  
 
 
Scheme 1. Reagents and conditions: (a) H2O2, AcOH, 50 
oC, 6 hr, 98 %;   (b) Aromatic aldehyde, cat. piperidine, pyridine, rt, 36 hr, 19 – 50%; (c) i. Sulfurous 
dichloride, EtOAc, reflux, 40 min, 100 %;  ii.  Aniline, anhydrous THF, reflux, 3 hr, 80-91%; (d) H2O2, AcOH, 0 
oC, 6 hr, 95 %;  (e) Fe0, AcOH/MeOH (1:2), 
reflux, 3 hr, 95-96 %   
 
 
Table 1  
Structure and growth inhibitory activity of selected compounds against human tumour cancer cells 
 
Compd 
Structure Cytotoxicity, 72h MTT (GI50, μM)
a
 
R R’ T47D MDA-468 HCT-116 MCF-7     MRC-5 
3a 2,4,6-(OMe)3 NO2 NT NT 1.31  1.75  5.81 
3b 2,3,4-(OMe)3 NO2 > 30 21.89  27.85  > 30 > 30 
3c 2,6-(OMe)2 NO2 > 30 5.46  10.22  13.71  > 30 
3d 3,5-(OMe)2 NO2 > 30 16.46  > 30 > 30 > 30 
3e 2,4,6-(OMe)3 NH2 NT 0.03  < 0.01 < 0.01 0.08  
3f 2,3,4-(OMe)3 NH2 5.90  3.48  5.31  5.95  > 30 
3g 2,6-(OMe)2 NH2 0.05  0.06  0.02  0.04  17.09  
3h 3,5-(OMe)2 NH2 0.53  0.52  0.54  0.49  > 30 
3i 2,4,6-(OMe)3 NHCOMe NT  NT 0.15  0.35  0.81  
3j 2,4,6-(OMe)3 NHCH2CO2H < 0.01 0.02  0.05  0.05  0.71  
4a H NO2 > 30 > 30 > 30 > 30 > 30 
4b 2,4,6-(Me)3 NO2 > 30 > 30 7.91  > 30 27.96  
4c 2,4,6-(OMe)3 NO2 > 30 > 30 18.80  > 30 > 30 
4d 2,5-(OMe)2 NO2 > 30 > 30 > 30 > 30 > 30 
4e NO2 NO2 > 30 > 30 > 30 > 30 > 30 
4f H NH2 > 30 > 30 > 30 > 30 > 30 
4g 2,4,6-(OMe)3 NH2 > 30 > 30 > 30 > 30 > 30 
7 2,4,6-(OMe)3 - 0.06  < 0.01 < 0.01 < 0.01 > 30 
a Values are means of at least three independent determinations.  NT:  not tested 
 
Anti-proliferative activity was assessed against colorectal 
carcinoma HCT-116, breast carcinoma MCF-7,  MDA-468, 
MDA-231 and T74D using a standard 72-h MTT cytotoxicity 
assay.
17
 The compounds were also tested against non-transformed 
lung fibroblast MRC-5. The results are summarized in Table 1.  
Most (E)-2-methoxy-5-(styrylsulfonylmethyl)anilines, 
particularly 3e, 3g, 3h, 3i and 3j, exhibited potent anti-
proliferative activity with GI50 < 1 M in cancer cells, except 
compound 3f  (R=2,3,4-(OMe)3) which has only modest activity 
(GI50 < 5 M). 3e and 3j (ON 01910) were the most potent anti-
proliferative agents with GI50 below 0.1 M; the 2,4,6-trimethoxy 
substituted styryl moiety seems important for the optimum 
potency observed. Interestingly, MRC-5 non-transformed cells 
appeared insensitive towards 3g and 3h, being < 280- and < 80-
fold less cytotoxic compared with the cancer cells tested. 
Replacement of the amino group on benzyl moiety in 3f, 3g and 
3h with nitro group resulting in corresponding analogue 3b, 3c 
and 3d abolished the activity. Compound 3a which contained the 
favourable 2,4,6-trimethoxylstyryl moiety gained some degrees 
of activity compared to its analogues 3b-3d. Replacement of the 
sulfonyl in 3e with sulfinyl afforded (E)-2-methoxy-5-((2,4,6-
trimethoxystyrylsulfinyl)methyl)aniline 7 which showed the 
excellent anti-tumour activity, being comparable to 3e. 
Significantly, compound 7 selectively killed cancer cells while 
sparing non-transformed MRC-5 cells. Replacement of 
styrylsulfonyl with sulfonyl-N-phenylacetamide was poorly 
tolerated and compounds 4a-4g were completely inactive in the 
assay 
The established structure activity relationship is shown 
schematically in Fig. 2. The styrylbenzylsulfonyl or 
styrylbenzylsulfinyl moiety is essential for potency, replacement 
with sulfonyl-N-phenylacetamide showing a dramatic loss in 
activity. Substitutions on the styryl ring system were generally 
found to be tolerated, although 2,4,6-trimethoxyl was the most 
favourable function. Substitutions with electron donating group 
on the benzyl ring system are expected to be amenable to 
optimization. In addition to amines, hydroxyl, thiol or their 
ethereal function should result in a more highly potent 
compound.  
 
Fig. 2. Summary of structure activity relationship 
 
The primary cellular mode of action of 7 was investigated 
when compared with 3j. The time-dependent growth inhibitory 
activity was examined in MDA468 cells. As shown in Table 2, 
both compounds exhibited comparable cytotoxicity and increased 
potency with extended time. We next examined the cell-cycle 
effects.
18
 Analyses by flow cytometry exposed severe 
perturbation of cell-cycle progression following treatment of cells 
with ≥ 0.5 M of 3j or 7 (Fig. 3). 20 h post treatment of MDA-
468 cells with 3j at 0.5 M (GI50) and 1 M (2xGI50) resulted in 
accumulation of G2/M events – 58% and 84% respectively. This 
was consistent with ON 01910 mechanism of action described 
previously.
15,3
 Compound 7 demonstrated a similar cell-cycle 
profile; treatment of the cells with 7 at 0.5 μM (GI50) and 1.0 M 
(2xGI50) causing 77 % and 85 % cells with G2/M DNA content 
respectively.  
Induction of apoptosis by the compounds was further analyzed 
by annexinV/PI double staining
18
 in MDA-468 cells following 
treatment with either 3j or 7 at 0.5 M, 1 M and 10 µM for a 
period of 20 hr. Both 3j and 7 induced significant numbers of 
apoptotic cells, effectively starting from 0.5 M in a dose-
dependent manner (Fig. 4). 
Table 2 
Time course MTT assay in MDA-468 cells 
Time (hr) 
Cytotoxicy, MTT (GI50, μM)
a 
3j 7 
24 0.601 ± 0.065 0.559 ± 0.095 
48 0.302 ± 0.021 0.137 ± 0.023 
72 0.014 ± 0.003 < 0.01 
a Represent as the mean of three independent assay ± s.d  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cell cycle analysis of MDA-468 cells following treatment with 
compound 3j or 7 for a period of 20 hr at the concentrations shown. Vertical 
bars represent the mean ± s.d. of three independent experiments. Values 
significantly (p < 0.05) different from DMSO vehicle control are marked with 
an asterisk (*). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Apoptosis of MDA-468 cells following treatment with 3j or 7 for 
20 hr at concentrations indicated. The percentage of cells undergoing 
apoptosis was defined as the sum of early apoptosis (annexin V-positive 
cells) and late apoptosis (annexin V-positive and PI-positive cells). Vertical 
bars represent the mean ± s.d. of three independent experiments. Values 
significantly (p < 0.05) different from DMSO vehicle control are marked with 
an asterisk (*). 
 
In conclusion, a series of benzylstyrylsulfonyl derivatives and 
benzylsulfonyl-N-phenylacetamides were prepared
19
 and the 
structure activity relationships were established. (E)-2-methoxy-
5-((2,4,6-trimethoxystyrylsulfinyl)methyl)aniline 7 possessed 
potent anti-proliferative activity against cancer cell lines, being 
comparable to 3j. Compound 7 showed similar cell-cycle effects 
to 3j and was capable of inducing cancer cells to apoptosis.  
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mmol) and 2,4,6-trimethoxybenzaldehyde (0.49 g, 2.5 mmol) 
were dissolved in mixture of anhydrous pyridine (10 mL) and 
anhydrous Piperidine (few drops). After stirring at rt for 36 hr the 
mixture was evaporated to give gummy brown residue which 
was dissolved in ethyl acetate (20 mL) and washed with 2N 
NaOH aq. (10 mL), 2N HCl aq. (10 mL), and distilled water (10 
mL). After being dried over anhydrous MgSO4, the organic 
solution was evaporated to afford a mixture of (E)-1,3,5-
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